Advanced

Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience

Elomaa, I; Blomqvist, C; Saeter, G; Nilbert, Mef LU ; Monge, O R; Wiebe, Thomas LU and Alvegård, Thor LU (1999) In Acta Orthopaedica Scandinavica. Supplementum 70(285). p.69-73
Abstract
During the past 15 years the Scandinavian Sarcoma Group has treated 140 patients with Ewing's sarcoma. Two protocols have been used. SSG IV included 52 patients between 1984 and 1990 and SSG IX, 88 patients since 1990. After 5 years of treatment, local recurrences occurred in 19% of the patients (M0 + M1) in the SSG IV group and 10% in the SSG IX group. Distant metastases developed in 57% of the M0-patients in the SSG IV group and in 33% in the SSG IX group. Tumor-related survival (overall) of M0-patients was 49% in SSG IV and 70% in SSG IX, and the metastasis-free survival rate 45% and 58%, respectively. Patients having a localized extremity tumor had a survival rate of 90% (SSG IX). In both treatment groups, good responders to... (More)
During the past 15 years the Scandinavian Sarcoma Group has treated 140 patients with Ewing's sarcoma. Two protocols have been used. SSG IV included 52 patients between 1984 and 1990 and SSG IX, 88 patients since 1990. After 5 years of treatment, local recurrences occurred in 19% of the patients (M0 + M1) in the SSG IV group and 10% in the SSG IX group. Distant metastases developed in 57% of the M0-patients in the SSG IV group and in 33% in the SSG IX group. Tumor-related survival (overall) of M0-patients was 49% in SSG IV and 70% in SSG IX, and the metastasis-free survival rate 45% and 58%, respectively. Patients having a localized extremity tumor had a survival rate of 90% (SSG IX). In both treatment groups, good responders to chemotherapy had a better survival rate than poor ones (SSG IV, p < 0.02, GI-II vs. G II-IV and SSG IX, p < 0.003, GI-III vs. G IV). In conclusions local control and survival rates were better with SSG IX than SSG IV. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Orthopaedica Scandinavica. Supplementum
volume
70
issue
285
pages
69 - 73
publisher
Taylor & Francis
external identifiers
  • pmid:10429626
  • scopus:0032769533
ISSN
0300-8827
language
English
LU publication?
yes
id
96bc97e6-897d-4bfb-8ac4-1a052d7af760 (old id 1115411)
date added to LUP
2008-07-08 09:13:22
date last changed
2017-01-01 06:41:16
@article{96bc97e6-897d-4bfb-8ac4-1a052d7af760,
  abstract     = {During the past 15 years the Scandinavian Sarcoma Group has treated 140 patients with Ewing's sarcoma. Two protocols have been used. SSG IV included 52 patients between 1984 and 1990 and SSG IX, 88 patients since 1990. After 5 years of treatment, local recurrences occurred in 19% of the patients (M0 + M1) in the SSG IV group and 10% in the SSG IX group. Distant metastases developed in 57% of the M0-patients in the SSG IV group and in 33% in the SSG IX group. Tumor-related survival (overall) of M0-patients was 49% in SSG IV and 70% in SSG IX, and the metastasis-free survival rate 45% and 58%, respectively. Patients having a localized extremity tumor had a survival rate of 90% (SSG IX). In both treatment groups, good responders to chemotherapy had a better survival rate than poor ones (SSG IV, p &lt; 0.02, GI-II vs. G II-IV and SSG IX, p &lt; 0.003, GI-III vs. G IV). In conclusions local control and survival rates were better with SSG IX than SSG IV.},
  author       = {Elomaa, I and Blomqvist, C and Saeter, G and Nilbert, Mef and Monge, O R and Wiebe, Thomas and Alvegård, Thor},
  issn         = {0300-8827},
  language     = {eng},
  number       = {285},
  pages        = {69--73},
  publisher    = {Taylor & Francis},
  series       = {Acta Orthopaedica Scandinavica. Supplementum},
  title        = {Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience},
  volume       = {70},
  year         = {1999},
}